There are no Transcripts on RIGL.
PR Newswire (Aug 13, 2014)
at CNBC.com (Jun 5, 2013)
at CNBC.com (Jun 4, 2013)
at Fox Business (Apr 5, 2013)
at MarketWatch.com (Oct 3, 2012)
at CNBC.com (Dec 1, 2011)
at CNBC.com (Apr 21, 2011)
Jul. 2, 2012, 2:38 PMPiper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax. | Comment!
RIGL vs. ETF Alternatives
Rigel Pharmaceuticals Inc is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
Other News & PR